The FDA’s addition of post-exposure prophylaxis for COVID-19 to the emergency use authorization for Regeneron Pharmaceuticals, Inc.’s monoclonal antibody therapy REGEN-COV (casirivimab and imdevimab) on 30 July marks the biggest advance yet for pre- and post-exposure prophylaxis strategies to manage SARS-CoV-2, which aim to reduce the chance that unvaccinated people in close contact with COVID-19 patients will become ill.
The revised EUA clears REGEN-COV for post-exposure prophylaxis in adults and children 12 years and up who weigh at least 40kg and are at high risk for progression to severe COVID-19
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?